Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics Announces CFO Transition
Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024
Intellia Therapeutics Names Brian Goff to its Board of Directors
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024